PAREXEL International Corporation s trend and data analysis indicates that the stock price has dropped -2.31% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -9.1% . Looking at the past 52 week period, the stock price is up at 4.54% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of PAREXEL International Corporation has a positive value of 16.02 compared to overall market.PAREXEL International Corporation is having a Relative Strength Index of 31.33 which indicates the stock is not yet over sold or over bought based on the technical indicators.
PAREXEL International Corporation (NASDAQ:PRXL) has tumbled 3.31% during the past week and has dropped 4.62% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 3.54%. PAREXEL International Corporation (NASDAQ:PRXL) has underperformed the index by 5.71% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Company shares have received an average consensus rating of Hold for the current week PAREXEL International Corporation (NASDAQ:PRXL) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.52 points or 0.82% at $63.13 with 1,852,555 shares getting traded. Post opening the session at $63.37, the shares hit an intraday low of $62.54 and an intraday high of $63.85 and the price was in this range throughout the day. The company has a market cap of $3,217 million and the number of outstanding shares has been calculated to be 50,954,585 shares. The 52-week high of PAREXEL International Corporation (NASDAQ:PRXL) is $72.32 and the 52-week low is $51.16.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.PAREXEL International Corporation was Downgraded by Credit Suisse to Neutral on Feb 6, 2017. PAREXEL International Corporation was Downgraded by Citigroup to Neutral on Feb 3, 2017. PAREXEL International Corporation was Downgraded by Deutsche Bank on Feb 3, 2017 to Sell, Price Target of the shares are set at $53.PAREXEL International Corporation was Downgraded by Raymond James to Underperform on Feb 2, 2017.
Company has reported several Insider transactions to the SEC, on Mar 6, 2017, Sybrand Pretorius (SVP, Chief Scientific Officer) sold 8,050 shares at 65.12 per share price.On Feb 16, 2017, Douglas A Batt (SVP, General Counsel & Sec.) sold 5,500 shares at 65.39 per share price.On Feb 10, 2017, Gadi Saarony (Senior Vice President, CRS) sold 2,325 shares at 64.54 per share price.
PAREXEL International Corporation Last issued its quarterly earnings results on Oct 26, 2016. The company reported $0.76 EPS for the quarter, missing the analyst consensus estimate by $ -0.10. Analyst had a consensus of $0.86. The company had revenue of $500.90 million for the quarter, compared to analysts expectations of $524.75 million. The companys revenue was down -2.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.70 EPS.
Parexel International Corporation is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales.